A new horizon in risk stratification of hepatocellular carcinoma by integrating vessels that encapsulate tumor clusters and microvascular invasion

Lianghe Lu(Sun Yat-sen University), Rong Guo(Sun Yat-sen University), Yihong Ling(Sun Yat-sen University), Chaoyun Huang(Sun Yat-sen University), Wu-Shen Yu(Dongguan People’s Hospital), Wei Wei(Zhujiang Hospital), Shaohua Li(Chinese Academy of Medical Sciences & Peking Union Medical College), Jiahong Wang(Guangzhou Medical University), Minshan Chen(Sun Yat-sen University), Yongfa Zhang(Taiyuan University of Technology), Chong Zhong(Guangzhou University of Chinese Medicine)
Hepatology International
April 9, 2021
10.1007/s12072-021-10183-w
Cited by 42

Related Papers

Global patterns of hepatocellular carcinoma management from diagnosis to death: the <scp>BRIDGE</scp> Study
|Liver International|2015|1.3k
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion
|JAMA Oncology|2019|559
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial
|The Lancet|2023|514
Camrelizumab Plus Apatinib in Patients With Advanced Cervical Cancer (CLAP): A Multicenter, Open-Label, Single-Arm, Phase II Trial
|Journal of Clinical Oncology|2020|217
Lenvatinib, toripalimab, plus hepatic arterial infusion chemotherapy <i>versus</i> lenvatinib alone for advanced hepatocellular carcinoma
|Therapeutic Advances in Medical Oncology|2021|216